Recruiting

Use of Biologics for Severe Asthma in Hong Kong

The landscape of biologics therapy used in Hong Kong is currently unknown. The purpose of this study is to conduct a retrospective analysis of the use of biologics treatment for severe asthma in Hong Kong. The study aims to assess the landscape of biologics usage, evaluate the characteristics and conditions of patients before and after receiving biologic therapy, and provide insights into the effectiveness and safety of these treatments in the local population.

ClinicalTrials.gov IDNCT06778746

PhaseNot Applicable

Enrollment360

SponsorChinese University of Hong Kong

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Asthma

About this study

Interventions

Other: no interventions — No interventions, this is an observational study

Primary outcomes

To determine the prevalence and patterns of biologics utilization for severe asthma in Hong Kong. (12 months)
To evaluate exacerbation rates before and after the initiation of biologic treatment. (12 months)
To evaluate the asthma control before and after the initiation of biologic treatment. (12 months)
To evaluate the lung function before and after the initiation of biologic treatment. (12 months)
To explore whether physicians are following international guidelines for the prescription of biologics (baseline)
To identify any adverse events associated with biologic therapy in the study population (12 months)

Eligibility information

Inclusion Criteria: * Patients aged 18 years or older. * Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines. * Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal) Exclusion Criteria: \- Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer

Study locations

Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK, Hong Kong, Hong Kong

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.